Menlo Therapeutics Inc公司档案_Menlo Therapeutics Inc股票代码_Menlo Therapeutics Inc公司概况 交行网上银行登陆
Menlo T 交行网上银行登陆herapeuti 交行网上银行登陆cs Inc公司介绍
Menlo Therapeutics Inc基本资料
| 证券代码： | MNLO | 上市板： | - |
| 证券名称： | Menlo Therapeutics Inc | 上市场所： | 纳斯达克交易所 |
| 证券类型： | - | 发行方式： | - |
| 首发上市日： | 首发价格( 交行网上银行登陆元)： | - | |
| 首发数量(股)： | - | 首发募资总额(USD/元)： | - |
| 公司名称： | Menlo Therapeutics Inc. | 注册地址： | 美国特拉华州 |
| 证券名称： | Menlo Therapeutics Inc | 上市场所： | 纳斯达克交易所 |
| 办公地址： | 200 Cardinal Way, 2nd Floor, Redwood City, California, USA | ||
| 董事会主席： | - | 成立日期： | 2011/10/01 |
| 公司属地： | United States 美国 | 电话： | +1 (650) 486-1416 |
| 公司网址： | www.menlotherapeutics.com | ||
| 公司介绍： | Menlo Therapeutics Inc. is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. It is concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for at least eight weeks despite treatment of any identified underlying cause. It believes that its product candidate, serlopitant, a highly selective once daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK1 R, has the potential to significantly alleviate itch and cough symptoms. Pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis, as well as refractory chronic cough, each represents a significant patient need. |
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.smctrader.com/zhengquangongsi/221183.html